Gene Editing and Human iPSCs in Cardiovascular and Metabolic Diseases


The incidence and the burden of cardiovascular disease (CVD), coronary heart disease (CHD), type 2 diabetes mellitus (T2DM), and the metabolic syndrome are greatly increasing in our societies. Together, they account for 31% of all deaths worldwide. This chapter focuses on the role of two revolutionary discoveries that are changing the future of medicine, induced pluripotent stem cells (iPSCs) and CRISPR/Cas9 technology, in the study, and the cure of cardiovascular and metabolic diseases.We summarize the state-of-the-art knowledge about the possibility of editing iPSC genome for therapeutic applications without hampering their pluripotency and differentiation, using CRISPR/Cas technology, in the field of cardiovascular and metabolic diseases. © 2023. The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

Authors Giallongo S, Lo Re O, Resnick I, Raffaele M, Vinciguerra M
Journal Advances in experimental medicine and biology
Publication Date 2023;1396:275-298
PubMed 36454473
DOI 10.1007/978-981-19-5642-3_18

Research Projects

Cell Lines